Research programme: toxoplasmosis therapeutics - Vyera Pharmaceuticals

Drug Profile

Research programme: toxoplasmosis therapeutics - Vyera Pharmaceuticals

Alternative Names: CDPK1 Inhibitor - Vyera Pharmaceuticals; DHFR Inhibitor - Vyera Pharmaceuticals; TRP 004; TRP 012; TRP 013; TUR 006

Latest Information Update: 12 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Turing Pharmaceuticals
  • Developer Vyera Pharmaceuticals
  • Class Antiparasitics; Small molecules
  • Mechanism of Action ATCDPK1 protein inhibitors; Tetrahydrofolate dehydrogenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Toxoplasmosis

Highest Development Phases

  • Preclinical Toxoplasmosis

Most Recent Events

  • 01 Sep 2017 Turing Pharmaceuticals is now called Vyera Pharmaceuticals
  • 04 Oct 2016 Turing Pharmaceuticals and Washington University in St. Louis agree to co-develop toxoplasmosis therapeutics for toxoplasmosis
  • 28 Nov 2015 Research programme: Dihydrofolate reductase inhibitors - Turing Pharmaceuticals is available for licensing in World as of 12 Nov 2015. http://www.turingpharma.com/
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top